Protagonist Therapeutics Inc
(PTGX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 176,724 | 207,340 | -78,955 | -106,290 | -72,185 |
| Depreciation Amortization | -2,800 | -795 | -1,257 | -741 | -562 |
| Accounts receivable | 9,957 | -290,043 | -9,990 | 10 | -29 |
| Accounts payable and accrued liabilities | 2,624 | 2,825 | -2,934 | -2,337 | 874 |
| Other Working Capital | 47,738 | -243,326 | -19,511 | -3,051 | -3,959 |
| Other Operating Activity | 6,950 | 296,570 | 42,411 | 25,213 | 15,276 |
| Operating Cash Flow | $241,193 | $-27,429 | $-70,236 | $-87,196 | $-60,585 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -270 | -242 | -609 | -590 | -186 |
| Purchase Of Investment | -240,627 | -65,671 | -191,045 | -93,077 | -34,122 |
| Sale Of Investment | 158,849 | 71,984 | 152,396 | 115,696 | 69,896 |
| Investing Cash Flow | $-82,048 | $6,071 | $-39,258 | $22,029 | $35,588 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 10,371 | 7,799 | 171,246 | 170,719 | 135,404 |
| Other Financing Activity | -600 | -600 | -769 | -769 | -769 |
| Financing Cash Flow | $9,771 | $7,199 | $170,477 | $169,950 | $134,635 |
| Beginning Cash Position | 186,952 | 186,952 | 125,969 | 125,969 | 125,969 |
| End Cash Position | 355,868 | 172,793 | 186,952 | 230,752 | 235,607 |
| Net Cash Flow | $168,916 | $-14,159 | $60,983 | $104,783 | $109,638 |
| Free Cash Flow | |||||
| Operating Cash Flow | 241,193 | -27,429 | -70,236 | -87,196 | -60,585 |
| Capital Expenditure | -270 | -242 | -609 | N/A | -186 |
| Free Cash Flow | 240,923 | -27,671 | -70,845 | -87,196 | -60,771 |